JASON OWYANG: Open Payments
NPI 1972928059 · SAN PABLO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$914 in 44 payments from 14 companies in 2025. Trend: 2023 $153 · 2024 $375 · 2025 $914
Food & beverage: $914
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 9 | $154 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $107 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $102 |
| GlaxoSmithKline, LLC. | 4 | $95 |
| Philips North America LLC | 3 | $92 |
| Novo Nordisk Inc | 4 | $74 |
| Lundbeck LLC | 3 | $71 |
| Edwards Lifesciences Corporation | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Boston Scientific Corporation | 1 | $28 |
Products named: Kerendia, MOUNJARO, JARDIANCE, MCOT, REXULTI, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), SHINGRIX, Ozempic.
Industry payments across CA — which companies pay providers there.
